ADA warns against compounded GLP-1 and dual GIP/GLP-1 receptor agonists

December 5, 2024

The American Diabetes Association (ADA) issued a statement advising against the use of compounded GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs). The recommendation comes in response to increased demand for and shortages of FDA-approved medications, leading to the rise of compounded alternatives.

ADA highlights significant concerns about the safety, quality, and efficacy of the compounded formulations that often bypass regulatory measures, resulting in potential variability in drug content and the inclusion of unapproved ingredients. The authors emphasize that these compounded versions may not meet FDA standards, posing risks to patients.

Physicians are advised to prioritize FDA-approved medications to ensure safety and efficacy. If FDA-approved options are unavailable, clinicians should carefully evaluate the risks and benefits of compounded alternatives and discuss these considerations with their patients.

Source:

Neumiller JJ, et al. (2024, December 2). Diabetes Care. Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association. https://pubmed.ncbi.nlm.nih.gov/39620926/